Overview

First-in-Human Trial of Oral AN2-502998

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
First-in-Human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998
Phase:
PHASE1
Details
Lead Sponsor:
AN2 Therapeutics, Inc